Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Adagene Inc. Market Cap
From what 0 stock analysts predict, the share price for Adagene Inc. (ADAG) might increase by 397.17% in the next year. This is based on a 12-month average estimation for ADAG. Price targets go from $4.8 to $18.81. The majority of stock analysts believe ADAG is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
ADAG is a stock in Healthcare which has been forecasted to be worth $10.54 as an average. On the higher end, the forecast price is $18.81 USD by from and on the lower end ADAG is forecasted to be $4.8 by from .
These are the latest 20 analyst ratings of ADAG.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Arthur He HC Wainwright & Co. | Buy | $5 | Reiterates | Sep 18, 2024 |
| Arthur He HC Wainwright & Co. | Buy | $5 | Reiterates | Jul 22, 2024 |
| Arthur He HC Wainwright & Co. | Buy | $5 | Reiterates | Jun 28, 2024 |
| Arthur He HC Wainwright & Co. | Buy | $5 | Reiterates | Oct 4, 2023 |
| Arthur He HC Wainwright & Co. | Buy | $5 | Reiterates | Sep 1, 2023 |
| Arthur He HC Wainwright & Co. | Buy | $5 | Reiterates | Apr 21, 2023 |
| Arthur He HC Wainwright & Co. | Buy | $5 | Reiterates | Mar 29, 2023 |
| Arthur He HC Wainwright & Co. | Buy | $5 | Reiterates | Mar 21, 2023 |
| Matthew Harrison Morgan Stanley | Overweight | $5 | Maintains | Jan 24, 2023 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $5 | Initiates | Dec 7, 2022 |
| Matthew Harrison Morgan Stanley | Overweight | $7 | Maintains | Sep 9, 2022 |
| Matthew Harrison Morgan Stanley | Overweight | $15 | Maintains | Feb 1, 2022 |
Morgan Stanley | Overweight | $27 | Maintains | Jan 6, 2022 |
| Matthew Harrison Morgan Stanley | Overweight | $33 | Maintains | Jul 16, 2021 |
China Renaissance | Buy | Initiates | Jun 25, 2021 | |
Jefferies | Buy | Initiates | Mar 8, 2021 | |
Morgan Stanley | Overweight | Initiates | Mar 8, 2021 |
When did it IPO
2021
Staff Count
174
Country
China
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Peter P. Luo Ph.D.
Market Cap
$95.6M
In 2023, ADAG generated $18.1M in revenue, which was a increase of 94.90% from the previous year. This can be seen as a signal that ADAG's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 09 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Adagene Inc. (Nasdaq: ADAG) will present posters at the SITC 39th Annual Meeting in Houston from Nov. 6-10, 2024, focusing on novel antibody-based therapies.
Why It Matters - Adagene's participation in a major scientific conference highlights its innovative therapies, potentially increasing investor interest and impacting stock performance.
Mon, 16 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - ADG126 at 10 mg/kg Q3W with pembrolizumab showed a 24% overall response rate in MSS CRC patients without liver/peritoneal metastases, with confirmed partial responses doubling to four.
Why It Matters - The doubling of confirmed partial responses in MSS CRC patients suggests promising efficacy for ADG126 with pembrolizumab, potentially boosting market interest and stock value in biotech firms involved.
Wed, 11 Sep 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Adagene Inc. (ADAG) and DaVita HealthCare (DVA) have been compared to their sector performance in 2023, indicating their relative standing in the market.
Why It Matters - Performance comparisons reveal how ADAG and DVA are faring against their peers, indicating potential growth or risks, which can influence investment decisions and portfolio adjustments.
Mon, 26 Aug 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Adagene Inc. (ADAG) and DaVita HealthCare (DVA) have shown performance metrics relative to their sector in 2023. Further details on specific performance figures are not provided.
Why It Matters - Performance comparisons indicate how ADAG and DVA are faring against sector trends, potentially influencing investor sentiment and future investment decisions.
Fri, 12 Jul 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Adagene Inc. (Nasdaq: ADAG) will present a poster at the ESMO Congress in Barcelona from September 13-17, 2024, focusing on antibody-based therapies.
Why It Matters - Adagene's poster presentation at a major medical congress may indicate progress in its drug development, potentially attracting investor interest and impacting stock performance.
Wed, 22 May 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Adagene Inc. (Nasdaq: ADAG) will participate in several investor conferences in June 2024, focusing on novel antibody-based therapies.
Why It Matters - Adagene's participation in investor conferences may indicate potential growth and increased visibility, influencing investor sentiment and stock performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
